理邦仪器(300206) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was CNY 383,997,814.73, representing a 2.08% increase year-on-year, while the year-to-date revenue decreased by 1.77% to CNY 1,241,682,027.20[4] - Net profit attributable to shareholders for Q3 2022 was CNY 39,306,511.87, a decrease of 40.25% compared to the same period last year, and year-to-date net profit decreased by 24.35% to CNY 189,735,741.06[4] - The basic earnings per share for Q3 2022 was CNY 0.0676, down 40.41% year-on-year, with diluted earnings per share also at CNY 0.0676[4] - In the first three quarters of 2022, the company achieved revenue of CNY 1,241.68 million, a year-on-year decrease of 1.77%[17] - The net profit attributable to shareholders for the same period was CNY 189.74 million, down 24.35% year-on-year[17] - Total operating revenue for Q3 2022 was CNY 1,241,682,027.20, a decrease of 1.3% compared to CNY 1,264,049,872.13 in Q3 2021[24] - Net profit for Q3 2022 was CNY 188,577,923.54, down 24.2% from CNY 248,602,011.37 in Q3 2021[25] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 98,139,816.77, a significant decrease of 49.44% compared to the previous year[12] - The net cash flow from operating activities was 98,139,816.77 CNY, a decrease of 49.5% compared to 194,111,890.50 CNY in the previous year[28] - The cash flow from operating activities totaled 1,306,919,352.25 CNY, an increase from 1,273,784,483.05 CNY year-over-year[28] - The total cash inflow from investment activities was 504,986,433.70 CNY, down 33.1% from 756,881,664.39 CNY year-over-year[28] - The net cash flow from investment activities was -126,541,115.79 CNY, compared to -17,220,929.06 CNY in the same period last year[28] - The net cash flow from financing activities was -190,833,375.63 CNY, a decrease of 40.6% from -321,490,730.44 CNY year-over-year[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,020,151,537.21, a decrease of 1.37% from the end of the previous year[4] - Cash and cash equivalents as of September 30, 2022, were CNY 529.95 million, down from CNY 733.91 million at the beginning of the year[20] - Total assets as of September 30, 2022, amounted to CNY 2,020.15 million, a decrease from CNY 2,048.11 million at the start of the year[21] - The company's current liabilities totaled CNY 196.72 million, down from CNY 284.06 million at the beginning of the year[21] - The total liabilities amounted to CNY 220,183,220.56, down from CNY 316,226,496.70 year-over-year[25] Expenses - The company's financial expenses decreased by 1541.83% year-on-year, primarily due to exchange rate fluctuations[10] - R&D expenses increased by 17.86% year-on-year, while sales expenses rose by 14.95%[17] - Total operating costs increased to CNY 1,092,270,292.18, up 4.0% from CNY 1,049,810,570.88 in the previous year[24] Business Segments - The patient monitoring business saw a year-on-year decline of approximately 20%, but this was a significant improvement from a nearly 60% decline in 2021[17] - The ultrasound imaging business experienced a growth rate exceeding 30% year-on-year[17] Strategic Plans - The company plans to increase investment in R&D and market expansion to address challenges in the international political and economic landscape[17]